Health Catalyst (NASDAQ:HCAT) Issues Earnings Results

Health Catalyst (NASDAQ:HCAT) posted its earnings results on Wednesday. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), Briefing.com reports. The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.49%. The company’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.22) EPS. Health Catalyst updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

Health Catalyst Stock Performance

NASDAQ HCAT traded down $0.62 during trading hours on Friday, hitting $8.24. 674,743 shares of the company’s stock were exchanged, compared to its average volume of 485,899. The business’s 50 day moving average is $8.07 and its 200-day moving average is $7.14. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.41. The firm has a market capitalization of $498.27 million, a P/E ratio of -6.10 and a beta of 1.32.

Analysts Set New Price Targets

A number of brokerages have issued reports on HCAT. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Royal Bank of Canada lifted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. JPMorgan Chase & Co. increased their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Finally, Stephens decreased their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.64.

Insider Buying and Selling at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,396 shares of company stock worth $266,280 in the last 90 days. 2.50% of the stock is owned by company insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.